XERS - Xeris Pharmaceuticals - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98422E1038
Glucagon, Therapy, Cortisol, Inhibitor, Injection
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Web URL: https://www.xerispharma.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
XERS Stock Overview
| Market Cap in USD | 351m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2018-06-21 |
XERS Stock Ratings
| Growth 5y | -50.2 |
| Fundamental | -46.6 |
| Dividend | 0.00 |
| Rel. Performance vs Sector | -0.53 |
| Analysts | 4.80/5 |
| Fair Price Momentum | 2.37 USD |
| Fair Price DCF | - |
XERS Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
XERS Growth Ratios
| Growth 12m | 3.16% |
| Growth Correlation 12m | 10% |
| Growth Correlation 3m | 62% |
| CAGR 5y | -26.16% |
| CAGR/Mean DD 5y | -0.36 |
| Sharpe Ratio 12m | -0.03 |
| Alpha vs SP500 12m | -31.54 |
| Beta vs SP500 5y weekly | 1.90 |
| ValueRay RSI | 84.42 |
| Volatility GJR Garch 1y | 70.62% |
| Price / SMA 50 | 17.57% |
| Price / SMA 200 | 19.72% |
| Current Volume | 1234k |
| Average Volume 20d | 1231.4k |
External Links for XERS Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of XERS stocks?
As of July 27, 2024, the stock is trading at USD 2.61 with a total of 1,233,985 shares traded.
Over the past week, the price has changed by +10.36%, over one month by +18.64%, over three months by +49.14% and over the past year by +0.00%.
As of July 27, 2024, the stock is trading at USD 2.61 with a total of 1,233,985 shares traded.
Over the past week, the price has changed by +10.36%, over one month by +18.64%, over three months by +49.14% and over the past year by +0.00%.
What are the forecast for XERS stock price target?
According to ValueRays Forecast Model, XERS Xeris Pharmaceuticals will be worth about 2.6 in July 2025. The stock is currently trading at 2.61. This means that the stock has a potential upside of +0.77%.
According to ValueRays Forecast Model, XERS Xeris Pharmaceuticals will be worth about 2.6 in July 2025. The stock is currently trading at 2.61. This means that the stock has a potential upside of +0.77%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 4.6 | 75.5 |
| Analysts Target Price | 4.9 | 87.7 |
| ValueRay Target Price | 2.6 | 0.77 |